Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline PLC (ADR) (GSK) Poised To Overtake Sanofi SA (ADR) (SNY) In This $1.8 Billion Market

GlaxoSmithKline PLC (ADR) (NYSE:GSK) is on the verge of leapfrogging Sanofi SA (ADR) (NYSE:SNY) in the meningococcal vaccine market in terms of sales. That is according to a report recently released by GlobalData. GSK’s rise is expected to be fuelled by a new drug launch and recent acquisitions.

GlobalData estimates that the meningococcal vaccine market will be worth $1.8 billion by 2025 compared to $1.1 billion last year, indicating annual growth of 5.4% for the decade. The expansion of the meningococcal vaccine market is expected to be driven by the launch of new drugs and an increase in national immunization programs.

Follow Glaxosmithkline Plc (NYSE:GSK)
Trade (NYSE:GSK) Now!

How GSK will leap over SNY

GSK’s market share uptake will primarily be driven by Bexsero. GlobalData predicts that sales of Bexsero will hit $570 million by 2025, thus exceeding the sales of Sanofi SA (ADR) (NYSE:SNY)’s Menactra. The launch of GSK’s other meningococcal vaccine drug called MenABCWY is further expected to add to the company’s market share gain.

mri, doctor, physicians, display, treatment, idea, medic, experiment, pharmaceutical, patient, future, interface, laboratory, multimedia, intelligence, male, digital, scan,

Wichy/Shutterstock.com

GSK’s MenABCWY, which is currently in Phase 2, is expected to launch in the U.S. and Europe by 2025. Therefore, GSK can be seen making a strong bid for the $1.8 billion revenue opportunity here.

Vaccine sales

GlaxoSmithKline PLC (ADR) (NYSE:GSK) generated $167 million and $232 million from sales of Bexsero and Menveo, respectively, in 2015.

For its part, Sanofi SA (ADR) (NYSE:SNY) generated $639 million from the sale of its meningococcal vaccine called Menactra. The company has another vaccine drug in the works.

Lucrative Deal

GlaxoSmithKline’s deal with the U.K. government to incorporate its drugs as part of the national immunization program helped fuel sales of the vaccine drugs in 2015. It is worth mentioning that GSK got hold of the drugs after an asset swap deal with Novartis AG (ADR) (NYSE:NVS) and it is that transaction that is expected to push GSK to the top of the meningococcal vaccine market.

GSK experienced such strong demand for its vaccine drugs in the U.K. national immunization program that there was a temporary shortage of the supplies at certain NHS clinics.

But on his way to the top, GlaxoSmithKline PLC (ADR) (NYSE:GSK) will have to deal with competition from Pfizer Inc. (NYSE:PFE)s Trumenba, which is expected to reach annual sales of $225 million by 2019.

Follow Sanofi Aventis (NYSE:SNY)
Trade (NYSE:SNY) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!